国际皮肤性病学杂志    2001 27 (6): 335-338   ISSN: 2096-5540  CN: 32-1880/R   霉酚酸酯在治疗系统性红斑狼疮肾脏损害中的应用 李建华综述1, 张振综述2, 曾抗审校1 1. 第一军医大学南方医院皮肤性病科; 2. 第一军医大学南方医院心胸外科 收稿日期 null  修回日期 null  网络版发布日期 null 参考文献  [1] Ishikawa H.Mizoribine and mycophenolate mofetil.Curr Med Chem,1999.6(7):575-597. [2] Eugui EM,Almquist S J,Muller CD,et al.Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro:role of deoxyguanosine nucleotide depletion.Scand J Immunol,1991,33(2):161-173. [3] Zeevi A.Woan M.Yao GZ.et al.Comparative in vitro studies on thr immunosuppressive activities of mycophenolic acid,bredinin,FK-506,cy closporine,and rapamycin.Transplant Proc,1991,23(6):2928-2930. [4] Grailer A,Nichols J,Hullett D,et al.Inhibition of human B cell respouses in vitro by RS-61443,cyclosporine A and DAB486IL-2.Trans-plant Proc,1991,23(1 Pt 1):314-315. [5] Lemster B,Woo J,Strednak J,et al.Cytokine gene expression in murine1ymphocytes activated in the presence of FK-506,bredinin,mycophenolicacid,or brequinar sodium.Transplant Proc,1992,24(6):2845-2846. [6] Jonsson CA,Erlandsson M.Svensson L,et al.Mycophenolate mofetilameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLlpr/lpr mice.Cell Im-munol.1999.197(2):136-144. [7] Jonsson CA,Svensson L,Carlsten H.Beneficial effect of the inosinemonophosphate dehydrogenase inhibitor mycophenolate imofetil on survival and se verity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.Clin Exp Immunol,1999,116(3):534-541. [8] Van Bmggen MC,Walgreen B,Rijke TP,et al.Attenuation of murine lupus nephritis by mycophenolate mofetil.J Am Soc Nephrol,1998,9(8):1407-1415. [9] McMurray RW,Elboume KB,Lagoo A,et al.Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW Flmouse model of systemic lupus erythematosus.J Rheumatol,1998.25(12):2364-2370. [10] Glicklich D,Acharya A.Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.Am J Kidney Dis,1998,32 (2):318-322. [11] Dooley MA,Cosio FG,Nachman PH,et al.Mycophenolate mofetil therapy in luvus nephritis:clinical observations.J Am Soc Nephrol,1999,10 (4):833-839. [12] Gaubitz M,Schorat A,Schotte H,et al.Mycophenolatemofetil for thetreatment of systemic lupus erythematosus:an open pilot trial.Lupus,1999,8(9):731-736. [13] Sollinger HW,Belzer FO,Deiehoi MH,et al.RS-61443 (mycophenolatemofetil):a multicenter study for refractory kidney transplant rejection.Ann Surg,1992,216:513-519. [14] David O,Taylor MD,R.Douglas Ensley,Stephanie L,Olsen et al.Mycophenolate mofetil(RS-61443):Preclinical,Clinical,and Three-year experience in heart transplantation.J Heart Lung Transplant.1994,13:571-582. [15] Renlund DG,Gopinathan SK,Kfoury AG,et al.Mycophenolate mofetil (MMF) in heart transplantation:rejection prevention and treatment Clin Transplant,1996,10(1 Pt2):136-139. [16] Dubrey SW,Holt DW,Banner-N.Measurement of mycophenolate mofetilplasma levels after heart transplantation and a potential side effect of highlevels.Ther Drug Monit,1999,21(3):325-326. [17] Sanchez V,Delgado JF,Blasco T,et al.Benefits of mycophenolate mofetilin cardiac transplant recipients with cyclosporine-induced nephropathy.Transplant-Proc,1999,31(6):2515-2516. 通讯作者: